SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R

被引：33
|
作者：
Sulkowski, M. S. [1 ]
Bourliere, M. [2 ]
Bronowicki, J. -P. [3 ]
Streinu-Cercel, A. [4 ]
Preotescu, L. [4 ]
Asselah, T. [5 ]
Pawlotsky, J. -M. [6 ]
Shafran, S. [7 ]
Pol, S. [8 ]
Caruntu, F. A. [4 ]
Mauss, S. [9 ]
Larrey, D. [10 ]
Haefner, C. [11 ]
Datsenko, Y. [11 ]
Stern, J. O. [12 ]
Kubiak, R. [11 ]
Boecher, W. [11 ]
Steinmann, G. [11 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Hop St Joseph, Marseille, France
[3] Hop Brabois, Vandoeuvre Les Nancy, France
[4] Prof Dr Matei Bals Inst Infect Dis, Bucharest, Romania
[5] Hop Beaujon, Clichy, France
[6] Hop Henri Mondor, F-94010 Creteil, France
[7] Univ Alberta, Edmonton, AB, Canada
[8] Hop Cochin, F-75674 Paris, France
[9] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany
[10] Hop St Eloi, Montpellier, France
[11] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[12] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60068-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
66
引用
收藏
页码：S30 / S30
页数：1
相关论文
共 50 条
  • [21] Improved Sustained Virologic Response (SVR) in "Difficult-to-Cure" Patients Treated With Telaprevir (T) in Combination With Peginterferon Alfa-2a (P) and Ribavirin (R): An Analysis From the PROVE3 Study
    Muir, Andrew J.
    Di Bisceglie, Adrian M.
    Adda, Nathalie
    Manns, Michael P.
    Terrault, Norah
    Bengtsson, Leif
    George, Shelley
    McHutchison, John
    GASTROENTEROLOGY, 2010, 138 (05) : S846 - S847
  • [22] HIGH SUSTAINED VIROLOGIC RESPONSE (SVR) AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2A/RIBAVIRIN
    Flamm, S.
    Lawitz, E.
    Jacobson, I.
    Rubin, R.
    Bourliere, M.
    Hezode, C.
    Vierling, J.
    Niederau, C.
    Sherman, M.
    Goteti, V.
    Vilchez, R.
    Brass, C.
    Albrecht, J.
    Poordad, F.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S541 - S542
  • [23] Association of Host Pharmacodynamic Effects and Virologic Response to Peginterferon Alfa-2a/Ribavirin in Patients With Chronic Hepatitis C
    Chung, Raymond T.
    Di Bisceglie, Adrian M.
    Poordad, Fred
    Hassanein, Tarek
    Zhou, Xiaolei
    Lentz, Ellen
    Prabhakar, Avi
    Hamzeh, Fayez M.
    GASTROENTEROLOGY, 2010, 138 (05) : S841 - S841
  • [24] ASSOCIATION OF HOST PHARMACODYNAMIC EFFECTS AND VIROLOGIC RESPONSE TO PEGINTERFERON ALFA-2A/RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C
    Chung, R. T.
    Di Bisceglie, A.
    Poordad, F. F.
    Hassanein, T.
    Zhou, X.
    Lentz, E.
    Prabhakar, A.
    Hamzeh, F. M.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S106 - S107
  • [25] HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN HCV GENOTYPE 1 RELAPSER PATIENTS RETREATED WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN FOR 72 WEEKS
    Kaiser, Stephan
    Lutze, Bettina
    Hass, Holer G.
    Werner, Christoph R.
    HEPATOLOGY, 2008, 48 (04) : 1140A - 1140A
  • [26] Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection A Retrospective Cohort Study
    Naing, Cho
    Sitt, Than
    Aung, Aye T. D.
    Aung, Kyan
    MEDICINE, 2015, 94 (30)
  • [27] PATIENT REPORTED OUTCOMES AMONG CHRONIC HEPATITIS C PATIENTS RETREATED WITH PEGINTERFERON ALFA-2A/RIBAVIRIN AFTER NON-RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN IN SPAIN
    Olveira, A.
    Rincon, D.
    Diago, M.
    Crespo, J.
    Calleja, J. L.
    Salmeron, J.
    Andrade, R.
    Romero, M.
    VALUE IN HEALTH, 2011, 14 (07) : A282 - A282
  • [28] LEUKOCYTE DECLINE PREDICTS SUSTAINED VIROLOGIC RESPONSE IN PATIENTS UNDERGOING PEGINTERFERON alfa-2b/RIBAVIRIN TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION
    Teuber, G.
    Mauss, S.
    Hueppe, D.
    Zehnter, E.
    Manns, M. P.
    Dahhan, T.
    Meyer, U.
    Witthoeft, T.
    Moeller, B.
    Dikopoulos, N.
    Brack, J.
    Hartmann, D.
    Dreher, B.
    Bilzer, M.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S376 - S376
  • [29] HCV core Ag as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alfa-2b plus ribavirin
    Buti, M
    Valdes, A
    Mendez, C
    Schaper, M
    Sauleda, S
    Rodriguez-Frias, F
    Jardi, R
    Esteban, R
    Guardia, J
    JOURNAL OF HEPATOLOGY, 2004, 40 : 138 - 138
  • [30] The influence of cumulative exposure to combination peginterferon alfa-2a (40 kd) (Pegasys) and ribavirin on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C
    Reddy, KR
    Fried, MW
    Shiffman, ML
    Hadziyannis, SJ
    Sette, H
    Morgan, TR
    Schaefer, S
    Popescu, M
    JOURNAL OF HEPATOLOGY, 2004, 40 : 149 - 149
12345